Phase III trial of concurrent and adjuvant temozolomide chemotherapy in non-1p/19q-deleted anaplastic glioma

See ANZCTR for full trial details >


Trial Summary:

CATNON aims to identify the benefits of different treatments for patients towards improving patient care. The main objectives are:

1. To determine whether chemotherapy given in addition to radiotherapy or the addition of chemotherapy after the completion of radiotherapy will improve overall survival and the time until tumour progression;

2. To document the effects of chemotherapy when either given at the same time as radiotherapy or after finishing radiotherapy; and

3. To identify patients most likely to benefit from this specific treatment on the basis of analysis of molecular markers from previously resected tumour specimens, which will ultimately allow the development of new treatments more specific to each patient's tumour characteristics.

Supported By:

Merck Sharp and Dohme; EORTC; Cancer Australia; NHMRC CTC; COGNO


Patients with non-1p/19q-deleted anaplastic glioma.

Registration ID:




Australian Lead Group:



Closed to recruitment; Patients in follow up

Activation Date:



Prof Martin van den Bent (international), Prof Anna Nowak